Distribution and characteristics of androgen receptor (AR) in breast cancer among women in Addis Ababa, Ethiopia: A cross sectional study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 20 10 2019
accepted: 13 04 2020
entrez: 7 5 2020
pubmed: 7 5 2020
medline: 1 8 2020
Statut: epublish

Résumé

Evaluation of the role of androgen receptor (AR) in the biology of breast cancer is an emerging area of research. There are compelling evidences that AR expression may be used to further refine breast cancer molecular subtyping with prognostic and therapeutic implications. Many studies indicated co-expression of AR with the hormonal receptors in breast cancer has a favorable prognosis. AR is also investigated by many researchers as a potential therapeutic target in treatment of breast cancer. Studies on the frequency and distribution of AR in breast cancer among Africans is barely available. Given the heightened interest to understand its role in breast cancer, we determined AR expression and assessed its association with clinicopathological parameters among Ethiopian women. In this study, 112 newly diagnosed patient with invasive breast cancer at Tikur Anbessa Specialized Hospital were enrolled. Immunohistochemical assessment of AR, ER, PR, Ki67 and HER2 were performed using tissue microarrays (TMA) constructed from their primary tumor block. Out of the 112 participants, 91 (81%) were positive for AR expression and the remaining 21 participants (19%) were negative for AR expression. Expression of AR in ER+, HER2+ and TNBC cases were 93%, 83% and 48% respectively. Our study reveals AR is expressed in a significant number of breast cancers patients and this may indicate that breast cancers cases in Ethiopia have favorable prognosis and could benefit from progresses in AR targeted treatments. Since AR expression has important consequences on the prognosis and treatment of breast cancer, further studies with an increased number of participants is necessary to confirm our reports.

Identifiants

pubmed: 32374753
doi: 10.1371/journal.pone.0232519
pii: PONE-D-19-29283
pmc: PMC7202607
doi:

Substances chimiques

AR protein, human 0
Biomarkers, Tumor 0
Receptors, Androgen 0
Receptors, Estrogen 0
Receptors, Progesterone 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0232519

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

Front Endocrinol (Lausanne). 2018 Oct 26;9:594
pubmed: 30416486
World J Clin Oncol. 2017 Apr 10;8(2):120-134
pubmed: 28439493
Ann Surg Oncol. 2013 Jan;20(1):87-93
pubmed: 22875649
Cancers (Basel). 2017 Jan 06;9(1):
pubmed: 28067809
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Ann Surg Oncol. 2015 Nov;22(12):3831-5
pubmed: 25743329
Curr Opin Endocrinol Diabetes Obes. 2016 Jun;23(3):249-56
pubmed: 26945136
Arch Pathol Lab Med. 2014 May;138(5):595-601
pubmed: 24236805
Cancer Treat Rev. 2015 Jun;41(6):547-53
pubmed: 25944485
Cancer Treat Rev. 2017 Dec;61:15-22
pubmed: 29078133
Front Med (Lausanne). 2017 Dec 08;4:227
pubmed: 29276709
Clin Cancer Res. 2011 Apr 1;17(7):1867-74
pubmed: 21325075
Clin Adv Hematol Oncol. 2016 Mar;14(3):186-93
pubmed: 27058032
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):458-470
pubmed: 28183824
Horm Cancer. 2018 Apr;9(2):82-94
pubmed: 29340907
Ann Surg Oncol. 2017 Oct;24(10):2876-2880
pubmed: 28766215
Clin Cancer Res. 2017 Jun 1;23(11):2702-2712
pubmed: 28151718
Breast Cancer Res. 2019 May 17;21(1):65
pubmed: 31101122
Br J Cancer. 2016 Jan 12;114(1):14-20
pubmed: 26757422
Ochsner J. 2017 Winter;17(4):405-411
pubmed: 29230126
Endocr Relat Cancer. 2016 Oct;23(10):R485-98
pubmed: 27528625
Cancers (Basel). 2019 Jul 17;11(7):
pubmed: 31319547
JAMA Oncol. 2017 Sep 1;3(9):1266-1273
pubmed: 28301631
Curr Oncol Rep. 2015 Feb;17(2):4
pubmed: 25665553
Front Endocrinol (Lausanne). 2018 Aug 28;9:492
pubmed: 30210453
J Breast Health. 2015 Apr 1;11(2):59-66
pubmed: 28331693
BMC Womens Health. 2018 Feb 14;18(1):40
pubmed: 29444670
Anticancer Res. 2017 Dec;37(12):6533-6540
pubmed: 29187427
Pharmacol Ther. 2019 Aug;200:135-147
pubmed: 31077689
Mol Endocrinol. 2012 Aug;26(8):1252-67
pubmed: 22745190
Int J Cancer Res Mol Mech. 2017 Apr;3(1):
pubmed: 28474005
Cancer Treat Rev. 2018 Jul;68:102-110
pubmed: 29940524
Front Endocrinol (Lausanne). 2018 Mar 29;9:137
pubmed: 29651273
BBA Clin. 2017 Jan 27;7:64-77
pubmed: 28194329
Crit Rev Clin Lab Sci. 2019 May;56(3):200-223
pubmed: 30821186
Cancers (Basel). 2016 Dec 02;8(12):
pubmed: 27918430
PLoS One. 2014 Feb 05;9(2):e88525
pubmed: 24505496

Auteurs

Endale Hadgu (E)

Department of Biochemistry, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.

Daniel Seifu (D)

Department of Biochemistry, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.

Wondemagegnhu Tigneh (W)

Department of Oncology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.

Yonas Bokretsion (Y)

Department of Pathology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.

Abebe Bekele (A)

Department of Surgery, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.

Markos Abebe (M)

Armauer Hansen research Institute (AHRI), Addis Ababa, Ethiopia.

Thomas Sollie (T)

School of Medical Sciences, Orebro University, Orebro, Sweden.

Christina Karlsson (C)

School of Health Sciences, Orebro University, Orebro, Sweden.

Mats G Karlsson (MG)

School of Medical Sciences, Orebro University, Orebro, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH